Destination therapy-time for a paradigm change in heart failure therapy

Swiss Medical Weekly

Volumn 143, Issue , 2013, Pages

  Wilhelm, Markus J ^a   Ruschitzka, Frank ^a   Falk, Volkmar ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Alternative To Transplant; Continuous Flow Pumps; Destination Therapy; Intermacs Level Of Heart Failure

Indexed keywords

ARTICLE; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; LIFE EXPECTANCY; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; QUALITY OF LIFE; SOCIAL SUPPORT; VENTRICULAR ASSIST DEVICE; HEART ASSIST DEVICE; PATIENT CARE PLANNING; REVIEW; TIME; TREATMENT OUTCOME;

HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; PATIENT CARE PLANNING; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877687239     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2013.13729     Document Type: Article

References (24)

1. Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report - 2011. J Heart Lung Transplant. 2011;30:1078-94.
2. Oosterlee A, Rahmel A. Eurotransplant International Foundation - Annual report 2011. http://www.eurotransplant.org
3. Swisstransplant Jahresbericht 2011. http://www.swisstransplant.org
4. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435-43.
5. El-Banayosy A, Deng M, Loisance DY, Vetter H, Gronda E, Loebe M, et al. The European experience of Novacor left ventricular assist (LVAS) therapy as a bridge to transplant: a retrospective multi-centre study. Eur J Cardiothorac Surg. 1999;15:835-41. (Pubitemid 29331960)
6. Frazier OH, Rose EA, Oz MC, Dembitsky W, McCarthy P, Radovancevic B, et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg. 2001;122:1186-95.
7. Goldstein DJ. Worldwide experience with the MicroMed DeBakey Ventricular Assist Device as a bridge to transplantation. Circulation. 2003;108(suppl1): II272-7. (Pubitemid 37099967)
8. Frazier OH, Myers TJ, Gregoric ID, Khan T, Delgado R, Croitoru M, et al. Initial clinical experience with the Jarvik 2000 implantable axialflow left ventricular assist system. Circulation. 2002;105:2855-60. (Pubitemid 34666098)
9. Schmid C, Tjan TD, Etz C, Schmidt C, Wenzelburger F, Wilhelm M, et al. First clinical experience with the Incor left ventricular assist device. J Heart Lung Transplant. 2005;24:1188-94. (Pubitemid 41247797)
10. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885-96. (Pubitemid 47347322)
11. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-51.
12. Fang JC. Rise of the machines - Left ventricular assist devices as permanent therapy for advanced heart failure. N Engl J Med. 2009;361:2282-5.
13. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. J Heart Lung Transplant. 2012;31:117-26.
14. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012;33:1787-847.
15. Boyle AJ, Ascheim DD, Russo MJ, Kormos RL, John R, Naka Y, et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant. 2011;30:402-7.
16. Slaughter MS, Meyer AL, Birks EJ. Destination therapy with left ventricular assist devices: patient selection and outcomes. Curr Opin Cardiol. 2011;26:232-6.
17. Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007;116:497-505. (Pubitemid 47450258)
18. Teuteberg JJ, Ewald GA, Adamson RM, Lietz K, Miller LW, Tatooles AJ, et al. Risk assessment for continuous flow left ventricular assist devices: does the destination therapy risk score work? An analysis of over 1,000 patients. J Am Coll Cardiol. 2012;60:44-51.
19. Lietz K. Destination therapy: patient selection and current outcomes. J Card Surg. 2010;25:462-71.
20. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson L, Miller M, et al. Long-term mechanical circulatory support (destination therapy): On track to compete with heart transplantation? J Thorac Cardiovasc Surg. 2012;144:584-603.
21. Jeevanandam V. Are we ready to implant left ventricular assist devices in "less sick" patients? Semin Thoracic Surg. 2012;24:8-10.
22. Stewart GC, Stevenson LW. Keeping left ventricular assist device acceleration on track. J Am Heart Assoc. 2011;123:1559-68.
23. Eckman P, Rosenbaum A, Vongooru H, Basraon J, Kamdar F, John R, et al. Survival of INTERMACS profile 4-6 patients after left ventricular assist device implant is improved compared to Seattle Heart Failure Model estimated survival. J Card Fail. 2011;17:S38-9.
24. Baldwin JT, Mann DL. NHLBI's program for VAD therapy for moderately advanced heart failure: the REVIVE-IT pilot trial. J Card Fail. 2010;16;855-8.